Linda T. Wang

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Jennifer L. Taylor‐Cousar, À. Munck, Edward F. McKone et al. · New England Journal of Medicine · 2017 · 765 citations · Full text

Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study

Margaret Rosenfeld, Claire Wainwright, Mark Higgins et al. · The Lancet Respiratory Medicine · 2018 · 262 citations · Full text

Medicine, Cftr Gating Mutation, Pediatrics +1

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study

John McNamara, Susanna A. McColley, Gautham Marigowda et al. · The Lancet Respiratory Medicine · 2019 · 126 citations

Medicine, Ivacaftor Combination Therapy, Pediatrics +1

The Use of White Blood Cell Count and Left Shift in the Diagnosis of Appendicitis in Children

Linda T. Wang, Kimball A. Prentiss, Jill Z. Simon et al. · Pediatric Emergency Care · 2007 · 111 citations

Bronchial Carcinoid Tumors in Pediatric Patients

Linda T. Wang, Earle W. Wilkins, Hans H. Bode · CHEST Journal · 1993 · 109 citations

Medicine, Pediatric Patients, Pediatrics +5